A Study to Analyze Intracerebral Hemorrhage Hematoma


About this study

The purpose of this study is to to take the usual waste material from the removal of hematoma and apply an array of -Omics approaches (including for example genomics, transcriptomics, lipidomics, proteomics, and metabolomics) to identify biomarkers that assess prognosis and identify key therapeutic targets.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male and female spontaneous intracerebral hemorrhage hematoma( ICH) patients >18 years of age admitted to Mayo Clinic Florida.
  • ICH documented by computed tomography (CT) or magnetic resonance imaging (MRI).
  • Neurosurgical management of ICH intended to remove the hematoma.

Exclusion Criteria: 

  • Refuse consent for pathological study and biomarkers.
  • Specimen obtained intraoperatively is not usable for whatever reason per Mayo clinic standards.
  • Aneurysmal ICH/subarachnoid hemorrhage or arteriovenous malformation-related bleeding as shown by CT angiogram/MR angiogram or digital subtraction angiography.
  • Medical management of ICH (i.e., no surgical clot evacuation).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Owen Ross, Ph.D.

Contact us for the latest status

Contact information:

Courtney Graddy B.S., M.H.A., CCRP



More information


Publications are currently not available

Mayo Clinic Footer